# Calon Cardio-Technology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/calon-cardio-technology

- Industry: Medical Devices & Equipment
- Headquarters: Swansea, UK
- Website: www.caloncardio.com
- Total disclosed funding: $2.4M
- Latest round: Series B (Feb 25, 2012)
- Investors on record: 2

## About

Calon Cardio-Technology Ltd focuses on developing advanced implantable heart pump solutions for chronic heart failure, enhancing cardiac support and improving patient life quality in critical healthcare markets.Calon Cardio-Technology Ltd is engaged in creating innovative heart pump technology that supports patients with chronic heart failure. Founded in 2007 and headquartered in Swansea, UK, the company has undergone strategic development to refine its offerings. The CEO is Peter Hinchliffe, while the founder, James A., has a history of entrepreneurship in the medical device sector. The company raised GBP 1.5 million in Series B funding on February 25, 2012, led by Longbow with participation from Development Bank of Wales, bringing the total amount raised to GBP 1.5 million.Calon Cardio-Technology Ltd specializes in the development of advanced implantable heart pump technology aimed at addressing chronic heart failure, a condition affecting over 20 million individuals in developed nations. The company's flagship product is an innovative heart pump designed to provide mechanical circulatory support, thereby enhancing cardiac output and improving the quality of life for patients suffering from heart failure. This pump assists the heart in effectively circulating blood, alleviating symptoms associated with the condition. The primary end users are patients diagnosed with chronic heart failure, and the technology is positioned within healthcare markets across Europe and North America, where the need for effective heart failure treatments is significant.The revenue for Calon Cardio-Technology Ltd in the most recent year, 2018, was GBP 0. The company's EBITDA for the most recent year, 2023, was GBP 0. Revenue is primarily derived from direct sales of their implantable heart pump technology to healthcare providers, including hospitals and cardiac care centers, through procurement agreements that facilitate bulk purchases for patient treatment options.The company plans to leverage the recent GBP 1.5 million raised in Series B financing to develop and launch new products aimed at enhancing treatment options for heart failure by expanding its implantable heart pump technology. Calon Cardio-Technology is also targeting expansion into new geographic markets, specifically focusing on regions across Europe and North America, with a timeline for entry set for the next two years. The funding will support product development, market research, and strategic partnerships necessary for successful market penetration.

## Funding rounds

- Series B, Feb 25, 2012, $2.4M — Longbow, Development Bank of Wales

## Investors

- Longbow (https://capitalatlas.ai/funds/longbow) — Series B
- Development Bank of Wales (https://capitalatlas.ai/funds/development-bank-of-wales) — Series B